Technetium-99m-EC and other potential new agents in renal nuclear medicine

被引:31
作者
Moran, JK [1 ]
机构
[1] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Nucl Med, Bronx, NY 10461 USA
关键词
D O I
10.1016/S0001-2998(99)80002-6
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Search for the ideal radiopharmaceutical to measure effective renal plasma flow (ERPF) has been underway since the early 1960s. Although ortho-iodohippuran (OIH) has biological properties suited for measurement of ERPF, the imaging characteristics are less than desirable. With the advent of the molybdenum-99/technetium-99m generators, efforts have focused on the development of a technetium-99m agent to measure ERPF. Over the last 10 to 15 years several promising technetium-99m renal imaging agents have been developed. Early examples of technetium-99m renal agents such as Tc-99m.CO(2)DADS and Tc-99m-PAHIDA, although not ideal replacements for OIH, demonstrated that a technetium-99m complex could be actively transported by the renal tubules and provided the impetus for development of new technetium-99m renal agents. The next breakthrough in technetium-99m renal agents was the development of the triamide mercaptide class of chelating agents by Fritzberg et al. To date the most promising compound in this class is mercaptoacetyltriglycine (MAG(3)). Tc-99m. MAG(3) is currently the agent of choice, but it is by no means the perfect replacement for OIH. Problems with high plasma protein binding and clearances that are only 50% to 60% of the OIH clearance make measurement of ERPF difficult. The serendipitous discovery that metabolites of the brain agent Tc-99m-ethylenedicysteine diethylester (Tc-99m-L,L-ECD) are rapidly excreted in the urine has led to the evaluation of Tc-99m-L,L-ethylenedicysteine (Tc-99m-L,L-ECD) as a potential renal imaging agent. Studies that have evaluated Tc-99m-L,L-EC in animals, normal human volunteers, and patients with various renal disorders reveal that the renal clearance of Tc-99m-L,L-EC is higher than Tc-99m. MAG(3) and more closely approaches that of OIH. Other approaches that are being examined in the development of the ideal renal imaging agent include substitution of various amino acids for glycine residue in MAG(3) and technetium-99m labeled organic cations. Copyright (C) 1999 by W.B. Saunders Company.
引用
收藏
页码:91 / 101
页数:11
相关论文
共 38 条
[1]  
ATLAS SA, 1986, ANNU REV MED, V37, P397
[2]   LOCALIZATION OF MONOCLONAL-ANTIBODY TNT-1 IN EXPERIMENTAL KIDNEY INFARCTION OF THE MOUSE [J].
CHEN, FM ;
WISNER, JR ;
OMACHI, H ;
RENNER, IG ;
TAYLOR, CR ;
EPSTEIN, AL .
FASEB JOURNAL, 1990, 4 (12) :3033-3039
[3]  
CHERVU LR, 1984, J NUCL MED, V25, P1111
[4]   A DEFINITION OF SUBSTRATE SPECIFICITY IN RENAL TRANSPORT OF ORGANIC ANIONS [J].
DESPOPOULOS, A .
JOURNAL OF THEORETICAL BIOLOGY, 1965, 8 (01) :163-+
[5]   TC-99M RENAL TUBULAR FUNCTION AGENTS - CURRENT STATUS [J].
ESHIMA, D ;
FRITZBERG, AR ;
TAYLOR, A .
SEMINARS IN NUCLEAR MEDICINE, 1990, 20 (01) :28-40
[6]  
ESHIMA D, 1987, J NUCL MED, V28, P1180
[7]  
ESHIMA D, 1986, CURRENT APPL RADIOPH, P237
[8]  
FRITZBERG AR, 1982, J NUCL MED, V23, P592
[9]  
FRITZBERG AR, 1986, J NUCL MED, V27, P111
[10]   Tc-99m-2GAM: A tracer for renal imaging [J].
Gianolli, L ;
Dosio, F ;
Matarrese, M ;
Colombo, F ;
Cutler, C ;
StepniakBiniakiewicz, D ;
Deutsch, E ;
Savi, A ;
Lucignani, G ;
Fazio, F .
NUCLEAR MEDICINE AND BIOLOGY, 1996, 23 (08) :927-933